Salute e Benessere
Primary Biliary Cholangitis (PBC) Treatment Market to Reach USD 2.72 Billion by 2033, Driven by Next-Generation FXR Agonists & Immunomodulators | DataM Intelligence
highlights multiple measurable factors accelerating market growth:
These metrics underscore a shift toward that deliver clinically meaningful liver function improvement.
(
The market includes , , , , and .
By 2033, the geriatric treatment segment is expected to cross , growing in line with global demographic shifts.
The U.S. accounted for approximately and is projected to surpass at .
Key quantitative drivers:
Japan's PBC treatment market reached , expected to rise to
at .
Key growth indicators:
According to , the market is moderately competitive with a blend of innovator companies, generics manufacturers, and emerging clinical-stage biotechs.
Pharmaceuticals, Inc. | Gilead Sciences, Inc. | Ipsen Biopharmaceuticals, Inc. | Teva Pharmaceutical
USA , Inc. | Glenmark Pharmaceuticals Inc. | AbbVie Inc. | Aden Healthcare | Zydus Therapeutics Inc. | COUR Pharmaceuticals | Kowa Company, Ltd. | Mirum Pharma | Parvus Therapeutics Inc. | GSK plc | Strides Pharma Science Limited | Calliditas Therapeutics AB
Collectively, top global players represent , reflecting strong clinical investments and regulatory momentum.
The is entering a new therapeutic era as next-generation FXR agonists, PPAR modulators, and immunomodulatory therapies reshape disease management. Growing from to , the sector is expanding at a steady .
According to , pharmaceutical innovators focusing on targeted, liver-specific mechanisms and long-term safety profiles will drive the next decade of clinical and commercial breakthroughs in PBC treatment.
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn, and Facebook.
Sai Kiran
DataM Intelligence 4market Research LLP
Ground floor, DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad , Telangana 500039
+1 877-441-4866
Sai.k@datamintelligence.com
Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo
View original content:https://www.prnewswire.co.uk/news-releases/primary-biliary-cholangitis-pbc-treatment-market-to-reach-usd-2-72-billion-by-2033--driven-by-next-generation-fxr-agonists--immunomodulators--datam-intelligence-302618302.html